March 22, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
| Attention: | Tracey Houser |
Kevin Vaughn
Christopher Edwards
Celeste Murphy
| Re: | Edgewise Therapeutics, Inc. Registration Statement on Form S-1 |
(File No. 333-253923)
Acceleration Request
| Requested Date: | Thursday, March 25, 2021 | |
| Requested Time: | 4:00 P.M. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Edgewise Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-l (File No. 333-253923) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041.
[Signature page follows]
| Sincerely, | |
| EDGEWISE THERAPEUTICS, INC. | |
| /s/ Kevin Koch | |
| Kevin Koch, Ph.D. | |
| President and Chief Executive Officer |
| cc: | R. Michael Carruthers, Edgewise Therapeutics, Inc. |
John Moore, Edgewise Therapeutics, Inc.
Tony Jeffries, Wilson Sonsini Goodrich & Rosati, P.C.
Melissa Rick, Wilson Sonsini Goodrich & Rosati, P.C.
Richard Segal, Cooley LLP
